Quantifying the Benefits and Risks of Methylphenidate as Treatment for Childhood Attention-Deficit/Hyperactivity Disorder

• Autores: Philip Shaw
• Localización: JAMA: the journal of the American Medical Association, ISSN 0098-7484, Vol. 315, Nº. 18, 2016, págs. 1953-1955
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Approximately 6% of school-aged children in the United States are prescribed medication for attention-deficit/hyperactivity disorder (ADHD), which is roughly 1 child in every classroom.1 Psychostimulants, such as methylphenidate, are the most commonly prescribed and have been a first-line medication for ADHD for more than 50 years.2 Establishing the efficacy and safety of methylphenidate in children is of the utmost importance. Meta-analyses, which quantitatively combine and critically evaluate the findings of trials, are important in this endeavor.